SCHEMBL16396262

SCHEMBL16396262

COC(=O)c1cc2cc(N)c(Br)cc2s1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 5/20 0.55
HDAC1 Q13547 3/20 0.47
HDAC3 O15379 2/20 0.43
HDAC4 P56524 2/20 0.43
HDAC7 Q8WUI4 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HDAC9 Q9UKV0 2/20 0.43
HDAC5 Q9UQL6 2/20 0.43
STING1 Q86WV6 7/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
GPR35 Q9HC97 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19433624 0.83 GPR35 (0.51) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL29636388 0.82 STING1 (0.61) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL16396339 0.82 HDAC1 (0.50) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL20022239 0.82 STING1 (0.61) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL16395880 0.82 GAA (0.48) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL13735896 0.82 PTPN2 (0.59) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL16396260 0.82 PTPN2 (0.49) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL16396073 0.82 STING1 (0.56) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL20563049 0.80 PTPN2 (0.64) PTPN2HDAC1HDAC3HDAC4HDAC7
SCHEMBL15897312 0.80 PTPN2 (0.56) PTPN2HDAC1HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562912-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2020-02-18 US disclosed
EP-3004057-B1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS C&C RES LAB (KR) 2018-07-25 EP disclosed
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2016-04-21 US disclosed
EP-3004057-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C Research Laboratories (KR) 2016-04-13 EP disclosed
WO-2014196793-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2014-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF STAT3, JAK2, STAT5A PTPN2 329/4885HDAC1 144/4885HDAC3 70/4885
US-10562912-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, STAT5A PTPN2 329/4885HDAC1 144/4885HDAC3 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.